The big driver here is that Aveo’s prior report of interim median progression-free survival (PFS) results of 8.4 months among the 163 patients enrolled in Study 902 was too low. Aveo’s final results have now indicated that there is a median PFS in this setting of 11.0 months. Even better, the median overall survival was 21.6 months.
Many analysts and articles calling CLLS the Next BLUE, CLLS actually better,covers more types of cancers then BLUE.
Sentiment: Strong Buy
J&J buys into Achillion's hep C pipeline for up to $1.1B
May 19, 2015 | By Damian Garde
Johnson & Johnson ($JNJ), fighting to keep up with the blockbuster race to launch quick cures for hepatitis C, has agreed to pay as much as $1.1 billion for the rights to Achillion Pharmaceuticals' ($ACHN) pipeline of antiviral treatments.
Under the deal, J&J is making a $225 million investment in its partner and promising up to $905 million in milestone payments in order to get its hands on a group of in-development hep C treatments. The plan is to develop Achillion's drugs in combination with one another and, ideally, come up with a regimen thatcan cure the infection in as few as four weeks. Leading the pipeline is ACH-3102, Achillion's Phase II NS5A inhibitor, followed by the complementary ACH-3422 and sovaprevir.
Investor Business Daily
CyberArk Q1 beat, will continue higher strong guidance, license growth
Conference call to be held on Monday, May 11, 2015 at 5:00 p.m. Eastern Time
- Positive momentum on clinical trials and research continues- Multiple strategic transactions furtherstrengthen technology platform and capabilities
- Strong quarter-end cash position of $447.6 million
typical before catalyst- someone wants in cheap, then watch them load up on shares.